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CD13/Aminopeptidase N (CD13) is known to play an important role in tumour cell invasion. We examined whether basic fibroblast
growth factor (bFGF) is involved in the regulation of CD13 expression in human melanoma cells. 1F6 human melanoma cells were
stably transfected with constructs encoding either the 18kDa (18kD) or all (ALL) bFGF isoform proteins. We observed highly
increased CD13mRNA and protein expression in the 1F6 clones regardless of the overexpression of either the 18kD or all isoform
proteins. Neutral aminopeptidase activity was increased five-fold and could be inhibited by bestatin and the CD13-neutralising
antibody WM15. The enhanced invasion through Matrigel, but not migration in a wound assay, was efficiently abrogated by both
bestatin and WM15. Upregulation of CD13 expression was the result of increased epithelial and myeloid promoter activity up to 4.5-
fold in 1F6-18kD and 1F6-ALL clones. Interestingly, in a panel of human melanoma cell lines, a significant correlation (r
2¼0.883,
Po0.05) between bFGF and CD13 mRNA and protein expression was detected. High bFGF and CD13 expression were clearly
related with an aggressive phenotype. Taken together, our data indicate that high bFGF expression upregulates CD13 expression
in human melanoma cells by activating both the myeloid and the epithelial CD13 promoter. In addition, we show that high bFGF and
CD13 expression results in enhanced invasive capacity and metastatic behaviour of human melanoma cells.
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Cutaneous melanoma is a type of skin cancer with high metastatic
potential. Melanoma cells can express a wide variety of (angio-
genic) growth factors, such as basic fibroblast growth factor
(bFGF), vascular endothelial growth factor (VEGF), platelet-
derived growth factor (PDGF) and interleukin-8 (IL-8). During
tumour development, melanoma cells depend on the autocrine
production of these growth factors for proliferation and survival
(Rodeck, 1993; Halaban, 1996) Most specifically, bFGF appears to
be a key signal in melanoma progression. Basic fibroblast growth
factor is involved in proliferation, migration and invasion of
tumour cells (Bikfalvi et al, 1997) We here report that bFGF over-
expression in human melanoma cells is responsible for upregu-
lation of CD13 resulting in a highly increased invasive capacity.
CD13/Aminopeptidase N (CD13) is a Zn
2þ-dependent type 2
transmembrane ectopeptidase of 150kDa that forms a noncova-
lently bound homodimer on the cellular membrane. Although
CD13 was first described to be a marker for haematopoietic cells of
myeloid origin, expression has been reported on non-haemato-
poietic cells and tissues, such as fibroblasts, brain cells, epithelial
cells of the liver, kidney and intestine. The C-terminal part of the
protein is located extracellularly and contains the active site
(Riemann et al, 1999). CD13 preferentially cleaves neutral amino
acids from small peptides rather than from large proteins. Because
of its broad substrate specificity, the functional role of CD13
strongly depends on the location of expression. Previous studies
have indicated that in the intestine, CD13 is involved in the
terminal degradation of small peptides and amino-acid scavenging
(Turner, 1986). In synaptic membranes in the brain, CD13 has
been shown to inactivate endorphins and enkephalins (Matsas
et al, 1985). In addition, CD13 participates in the processing of
peptides presented by the major histocompatibility complex class
II molecule (Hansen et al, 1993; Larsen et al, 1996). Furthermore,
CD13 acts as the receptor for the transmissible gastroenteritis virus
and the human coronavirus (Delmas et al, 1992).
High expression of CD13 can be detected in a number of human
solid tumours, including melanoma (Menrad et al, 1993; Saiki
et al, 1993; Fujii et al, 1995; Ishii et al, 2001; Hashida et al, 2002;
Ikeda et al, 2003; Kehlen et al, 2003; Van Hensbergen et al, 2004),
and a soluble form of CD13 has been shown to be highly increased
in intratumoral fluids and ascites (Van Hensbergen et al, 2002).
Few observations have been done with regard to the functional role
of CD13 in malignancies. In melanoma cells, CD13 was reported to
act as an auxiliary adhesion molecule that translocates to sites of
cell–cell contact (Menrad et al, 1993). In renal cell carcinoma,
fibrosarcoma and melanoma cell lines, CD13 facilitates invasion by
degradation of the extracellular matrix (ECM) (Menrad et al, 1993;
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sSaiki et al, 1993; Fujii et al, 1995). CD13 is also involved in tumour
angiogenesis, since CD13 is present on tumour endothelial cells,
but not on existing blood vessels in normal tissues (Pasqualini
et al, 2000).
Menrad et al (1993) have been the first to describe the presence
of CD13 on melanoma cells, whereas CD13 expression could not be
detected on normal melanocytes. Moreover, CD13 expression
becomes increasingly prevalent during the process of melanoma
progression (Elder et al, 1989; Menrad et al, 1993) and is directly
associated with ECM degradation and invasion. Transfection of
CD13 into A375M and A2058 human melanoma cells resulted
in increased degradation of type IV collagen and invasion in ECM.
It was suggested that CD13 may serve as an activator of type IV
collagenase required for the invasive and metastatic phenotype of
melanoma cells (Fujii et al, 1995).
The expression of CD13 is regulated by two distinct cell type-
specific promoters, the proximal or epithelial promoter and the
distal or myeloid promoter. The epithelial promoter is mainly
active in epithelial cells of the intestine, kidney, liver and brain
and in endothelial cells, while the myeloid promoter is active in
monocytes, myeloid leukaemia cells and fibroblasts (Shapiro et al,
1991). The two promoters are regulated by different transcription
factors, but both transcripts result in expression of the same
protein. In addition, both promoters are thought to be activated in
a mutually exclusive manner (Shapiro et al, 1991). In endothelial
cells, CD13 mRNA and protein expression can be transcriptionally
upregulated in response to diverse factors influencing the tumour
microenvironment, such as hypoxia and increased presence of
angiogenic growth factors such as bFGF, VEGF, tumour necrosis
factor a (TNFa) and insulin-like growth factor-1 (IGF-1) (Bhagwat
et al, 2001). The upregulation of CD13 in endothelial cells was
shown to be mediated through activation of the proximal promoter
of CD13, while its regulation in melanoma cells remains to be
determined.
We recently observed that overexpression of bFGF in human
1F6 melanoma cells resulted in an accelerated in vitro and in vivo
growth rate. 1F6 clones displayed a different morphology, suggest-
ing changes in the expression of adhesion molecules (Fontijn
et al, unpublished data). Since CD13 has been implicated in
melanoma invasion, we determined whether this protein was
upregulated in our bFGF-overexpressing 1F6 clones. We here
report that bFGF induces the expression of CD13 in human
melanoma cells resulting in a highly increased invasive capacity.
In addition, we report that both CD13 promoters are activated
upon upregulation of CD13 by bFGF. Furthermore, we found a
strong correlation between bFGF and CD13 expression in a panel
of human melanoma cell lines.
MATERIALS AND METHODS
Cell culture
The human melanoma cell lines BLM, Mel57, M14 and 1F6 were a
kind gift of Dr JR Westphal and Dr W Leenders, University
Medical Centre, St Radboud Nijmegen, Netherlands, and have
been established from surgically removed melanoma metastases
(Van Muijen et al, 1991). The BRO cell line has been derived from
a highly malignant and aggressive primary melanoma (Lockshin
et al, 1985). Hep3B human hepatocellular carcinoma cells, HL60
human promyelocytic leukaemia cells and U937 human histiocytic
lymphoma cells were obtained from American Type Culture
Collection (ATCC, Manassa, VA, USA). Cell lines and 1F6 clones
highly (H) or lowly (L) overexpressing the 18kD isoform of
human bFGF (1F6-18kD-H and 1F6-18kD-L), all isoforms of bFGF
(1F6-ALL-H and 1F6-ALL-L) or control empty vector cells
(1F6-pcDNA3) have been described (Fontijn et al, unpublished
data). Cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM; Bio Whittaker, Verviers, Belgium) supplemented with
10% heat-inactivated fetal calf serum (FCS; Gibco Invitrogen,
Breda, the Netherlands), 50Uml
 1 penicillin (ICN Biochemicals,
Zoetermeer, the Netherlands) and 50mgml
 1 streptomycin (ICN
Biochemicals). In addition, bFGF-overexpressing 1F6 clones were
cultured in the presence of 500mgml
 1 geneticin (Gibco/Invitro-
gen) to maintain selection for bFGF overexpression. All cells were
grown at 371C in humidified air containing 5% CO2.
Isolation of RNA and RT–PCR
Total RNA of cell lines was isolated using Trizol reagent (Gibco/
Invitrogen) according to the manufacturer’s protocol. RNA
(3mg) was reverse-transcribed with 50U MMLV reverse transcrip-
tase (Invitrogen) in the presence of 1.2ml 0.5mgml
 1 random
primers.
Quantitative Light Cycler RT–PCR was used to determine bFGF
and CD13 mRNA in melanoma cells and bFGF-overexpressing 1F6
clones (Van Hensbergen et al, 2003) mRNA was analysed with the
LightCycler-Faststart DNA Master Hybridization Probes kSYBR
Green 1 kit (Roche Diagnostics, Mannheim, Germany). The human
bFGF (sense: 50-TGTGCTAACCGTTACCTGGC-30, antisense: 50-AT
AGCTTTCCCAGGTCC-30), CD13 (sense: 50-GTAATACGACTCACT
ATAGGGCCAGGGGCCTGTACGTTTTTA-30, antisense: 50-AATTA
ACCCTCACTAAAGGGCCACCAGCTCAGTCTTGTCA-30) and, as
internal controls, human b2-microglobulin (sense: 50-GATGAGTA
TGCCTGCCGTGTG-30,a n t i s e n s e :5 0-CAATCCAAATGCGGCATCT-30),
GAPDH (sense: 50-ACCACAGTCCATGCCATCAC-30, antisense:
50-TCCACCACCCTGTTGCTGTA-30) and PDGB (sense: 50-TCCAA
GCGGAGCCATGTCTG-30, antisense: AGAATCTTGTCCCCTGTGG
TGGA-30) genes were amplified according to the manufacturer’s
protocol. In short, the reaction mix contained 4mM MgCl2, 0.5mM
sense and antisense primer, 1 FastStart DNA Master SYBR
Green 1 mix (containing LightCycler-Faststart Enzyme, FastStart
Taq DNA polymerase, SYBR green dye, dNTPs and reaction
buffer) and 2ml cDNA. Polymerase chain reaction conditions were
as follows: 951C for 10min followed by 40 cycles at 951C for 10s,
601C for 10s and 721C for 22s. cDNA was replaced by PCR-grade
water as a negative control. Relative expression levels of different
samples were calculated from bFGF crossing points normalised
to b2-microglobulin. Relative mRNA expression was calculated
by: (E
DCp target gene)/(E
DCp reference gene), in which E¼efficiency and
DCp¼crossing point when compared to 1F6 or 1F6-pcDNA3 cells.
Primer efficiencies were determined using pooled cDNAs.
In experiments designed to investigate the effect of bFGF
overexpression on CD13 mRNA stability, cells were made
quiescent in serum-free medium for 24h. Next, cells were
preincubated with 1mgml
 1 actinomycin D (Sigma-Aldrich
chemie, Zwijndrecht, the Netherlands) for 1h in serum-free
medium (time point¼0h) and, thereafter, harvested after incuba-
tion for 1, 2, 3 and 5h with 1mgml
 1 actinomycin D in serum-free
medium. At each time –point, CD13 mRNA levels were determined
by Light Cycler RT–PCR.
Expression of fragments derived from activity of the myeloid
(MP) or both the myeloid and epithelial (MP/EP) promoters of
CD13 was determined by RT–PCR. In total, 2ml cDNA was subjec-
ted to 38 PCR cycles with the sense primers CD13 MP: 50-AGTCCA
GGGTCCAGGTTCCA-30 and CD13 MP/EP: 50-ATGGCCAAGGGCT
TCTATAT-30 and the shared antisense primer CD13 MP/EP: 50-AC
GCTTTACTTTGGTCCAA-30. As an internal control, b2-micro-
globulin expression was detected in the same samples. Polymerase
chain reaction conditions were as follows: 3min hotstart at 941C
followed by a 30s denaturation step at 941C, annealing at 561C for
30s, elongation at 721C for 30s. Amplification products were sepa-
rated on a 1% agarose gel containing 1mgml
 1 ethidium bromide
(Invitrogen) and analysed in a qualitative way using a Geldoc
system (Bio-rad Laboratories, Veenendaal, the Netherlands).
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sWestern blot
Melanoma cell lines and bFGF-overexpressing 1F6 clones were lysed
in ice-cold FOS-RIPA lysis buffer (10mM Tris-HCl, 150mM NaCl,
0.1% SDS, 0.1% NP-40 and 0.1% sodium deoxycholate) supple-
mented with 0.5mM trypsin inhibitor (Sigma-Aldrich), 0.5mgml
 1
leupeptin (Sigma-Aldrich), 1mM PMSF (Merck, Amsterdam, the
Netherlands), 0.1mM sodium ortho vanadate (Sigma-Aldrich)
and 50mM sodium fluoride (Baker Chemicals, Deventer, the
Netherlands) for 10min on ice. Lysates were centrifuged for
15min at 13000r.p.m. at 41C to remove debris. Protein concentra-
tions of cell lysates were measured according to Bradford (1976).
Proteins were denatured by addition of sample buffer containing
b-mercapto ethanol and incubation at 951C for 5min. Proteins
were subjected to SDS–PAGE on a 12% polyacrylamide gel and
electrophoretically transferred to a polyvinylidene difluoride
membrane (Immobilon; Millipore, Etten-Leur, the Netherlands).
Membranes were blocked for 1h in TBST (10mM Tris pH 8,
150mMl
 1 NaCl and 0.025% Tween 20)/5% milk and incubated
overnight with 0.2mgml
 1 rabbit polyclonal human bFGF-directed
antiserum (sc-79; Santa Cruz Biotechnology, Heerhugowaard,
the Netherlands) or 0.5mgml
 1 mouse polyclonal human CD13-
directed antiserum (3D8; Santa Cruz Biotechnology) in TBST/5%
milk. After washing with TBST, bFGF and CD13 membranes
were incubated for 1h at room temperature with, respectively,
horseradish peroxidase-conjugated mouse anti-rabbit IgG (1:2000
dilution; Cell Signalling Technology, Heerhugowaard, the
Netherlands) or with horseradish peroxidase-conjugated rabbit
anti-mouse IgG (dilution 1:500; DAKO Cytomation, Heverlee, the
Netherlands) in TBST/5% milk. Membranes were washed and
proteins were visualized by electro-chemiluminescence.
Fluorescence-activated cell sorter analysis
Cells at 70% confluence were harvested by short trypsinisation,
washed and resuspended in phosphate-buffered saline (PBS)
containing 0.1% bovine serum albumin (BSA) and 0.05% NaNO3.
1 10
5 cells were incubated at room temperature for 30min
with 1:20 diluted phycoerythrin (PE)-conjugated anti-human
CD13 monoclonal antibody L-138 (BD biosciences, Alphen aanden
Rijn, the Netherlands), PE-conjugated mouse IgG1 or PBS.
Cells were washed and analysed on a FACS calibur flow cytometer
(BD biosciences). Results were expressed as the ratio of the mean
fluorescence of L-138 divided by that of IgG1.
Aminopeptidase activity assay
Surface aminopeptidase activity was measured by plating 5000
cells in 10% serum in a 96-well plate according to Van Hensbergen
et al (2002). After a 6-h incubation period, medium was removed
and fresh serum-free medium containing 0.1% BSA was added.
After 16h, cells were washed with PBS and incubated with 100ml
alanine-AMC (L-alanine-4-methyl-7-coumarinylamide trifluoro-
acetate; Sigma-Aldrich) in the absence or presence of 350mM
bestatin (Sigma-Aldrich) or 10mgml
 1 CD13-neutralising mouse
monoclonal antibody WM15 (BD biosciences). Release of the
fluorescent product 7-AMC was monitored every 5min during
1h in a Spectrafluor multiplate reader (Tecan, Salzburg, Austria)
with excitation wavelength l
360nm and emission wavelength
l
465nm. The neutral aminopeptidase activity was calculated from
the slope of the fluorescence–time curve, using a calibration curve
of 7-AMC (Sigma-Aldrich).
Migration assay
Cells were seeded in 24-well plates and grown to confluence. A
wound was scratched in the confluent cell layer with a sterile
pipette tip in two directions. Medium was replaced by medium
without or with 10mgml
 1 mouse IgG, 10mgml
 1 WM15 or 350mM
bestatin. Immediately after wounding and at time points 6, 12
and 24h, wounds were photographed at  25 magnification with
a confocal laserscan microscope (Leica TCS 4D; Leica, Jena,
Germany) and a video camera attached to a computer with Leica
Q500MC software (Leica). The width of the wounds was measured
in four areas at all time points and compared to the original wound
at time point 0h. Possible toxicity of IgG, WM15 and bestatin was
determined by performing a parallel MTT (3-(4,5-dimetylthiazol-
2-yl)-2,6-dimethyl-morpholino)-2,5-diphenyl-tetrazolium bromide;
Sigma-Aldrich) assay (Mosmann, 1983) using four replicate wells
and an exposure time of 24h. Cell growth of untreated cells was set
at 100% and growth of treated cells was expressed as a percentage
of control cell growth.
Matrigel invasion assay
The Matrigel invasion assay was performed in a 24-well plate
transwell system (Van Hensbergen et al, 2003). Filters with 8mm
pore size (HTS Fluoroblok Insert; Becton Dickinson labware,
Le Pont de Claix, France) were coated on the lower side with 1%
fibronectin (Merck) for 2h and washed with PBS before coating
the upper side of the filter with Matrigel (5 or 20mgfilter
 1; Sigma-
Aldrich). DMEM containing 10% FCS was added to the lower
compartment. 2 10
5 cells in DMEM containing 0.5% FCS in a
volume of 200ml were added to the upper compartment. In control
wells, 0.5% FCS was added to both the lower and the upper
compartment. For inhibition of invasion, 350mM bestatin was
added to both the upper and the lower compartment. WM15
(10mgml
 1) was present in the upper compartment only, and this
included a 1-h preincubation period before the cells were seeded.
Cells were allowed to invade for 48h at 371C. Invasion was
quantified by exposing the cells in the lower compartment to
5mM calcein-AM (Molecular Probes, Leiden, the Netherlands) at
371C during the final 30min of the assay. Calcein-AM is the
acetoxy-methyl ester of calcein, which diffuses readily through
the cell membrane. In the cytosol, calcein-AM is converted into
the fluorochrome calcein by esterases. Calcein fluorescence in
the lower compartment was measured in a Spectrafluor multi-
plate reader (Tecan) with excitation wavelength l
492nm and
emission wavelength l
535nm. Cytotoxicity of WM15 and bestatin
was determined by performing a parallel MTT assay with an
exposure time of 48h in a similar way as described for the
migration assay.
Transient transfection and dual luciferase assay
The CD13 promoter-luciferase reporter constructs BstXI-lucifer-
ase, encoding the epithelial promoter and CD13-1.15-luciferase,
encoding the myeloid promoter, were a kind gift of Dr LH Shapiro
and have been described previously (Bhagwat et al, 2001). pGL2
basic-luciferase and pRenilla luciferase-CMV were purchased from
Promega (Leiden, the Netherlands). Exponentially growing 1F6
cells and bFGF-overexpressing 1F6 clones in duplicate wells of six-
well plates were transiently transfected with 0.5mg of each reporter
plasmid for 48h using Fugene 6 transfection reagent (Roche
Diagnostics) following the manufacturer’s protocol. Cotransfection
with 5ng pRenilla luciferase-CMV (pRL-CMV) was performed to
correct for possible differences in transfection efficiency. The
activities of firefly and Renilla luciferase were determined with the
dual luciferase reporter assay (Promega) following the manufac-
turer’s protocol. In short, cells were lysed by scraping in the
presence of 250ml1  passive lysis buffer. In total, 20ml of cell
lysate was transferred into the luminometer tube containing 100ml
LAR II buffer (Promega), and firefly luciferase activity was
measured. Consecutively, Renilla luciferase activity was measured
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safter adding 100ml of Stop & Glo Reagent (Promega). Relative
CD13 promoter activity in 1F6 cells and bFGF-transfected clones
was calculated by the formula:
ðCD13fireflyluciferasevalueÞ=ðpRL   CMVRenillaluciferasevalueÞ
ðpGL2   basicfireflyluciferasevalueÞ=ðpRL   CMVRenillaluciferasevalueÞ
:
Statistical analysis
Statistical analysis of possible differences between mean values
was performed with a two-tailed Student’s t-test. Po0.05 was
considered significant.
RESULTS
Characteristics of bFGF-overexpressing 1F6 cells
Recently, we characterised 1F6 melanoma cells stably transfected
with the 18kD isoform of bFGF, ALL isoforms of bFGF or a control
empty vector pcDNA3 (Fontijn et al, unpublished data). The
overexpressed bFGF was biologically active in a human umbilical
vein endothelial cell (HUVEC) proliferation assay. Changes in cell
morphology were observed in 1F6 cells overexpressing both the
18kD and ALL bFGF isoforms. In contrast to 1F6 cells, which are
large cells with numerous dendritic cell processes, 1F6-18kD and
1F6-ALL cells appeared smaller, were more rounded and formed
less dendritic cell processes. In addition, significantly accelerated
in vitro and in vivo growth rates up to, respectively, two- and
three-fold were observed in 1F6 cells and tumours overexpressing
either 18kD or ALL bFGF isoforms (Fontijn et al, unpublished
data). Since these changes in morphology and growth rate might
be indicative for increased aggressive behaviour, we determined
whether CD13 expression was upregulated in bFGF-overexpressing
1F6 cells.
CD13 expression and activity is increased in 1F6 cells
overexpressing 18kD or ALL isoforms of bFGF
bFGF mRNA and protein expression in 1F6-pcDNA3 cells and 1F6
clones lowly or highly overexpressing 18kD (18kD-L, 18kD-H) or
ALL (ALL-L, ALL-H) isoforms of bFGF are visualised in Figure 1.
Increased CD13 mRNA expression up to 150-fold was observed
in 1F6-18kD as well as in 1F6-ALL clones as compared to the
expression level in 1F6-pcDNA3 (Figure 2A). Figure 2B shows
CD13 mRNA expression in the same clones, but normalised for
two other reference genes GAPDH and PDGB. A similar pattern
of CD13 upregulation was observed, although the absolute fold
increase over 1F6-pcDNA3 CD13 expression levels varied with
the reference gene of choice. GeNorm analysis (Vandesompele
et al, 2002) indicated that among the reference genes, human
b2-microglobulin and GAPDH were the most stable in our model
(data not shown). High expression of CD13 in bFGF-transfected
1F6 clones was confirmed on the protein level by Western blot
(Figure 2C). Fluorescence-activated cell sorter analysis also
confirmed high CD13 protein expression, which was increased
up to 450-fold in bFGF-overexpressing 1F6 clones (Figure 2D).
CD13 expression in 1F6 clones was up to two-fold higher than that
in the BRO cell line, which contains high levels of endogenous
CD13.
To test whether the overexpressed CD13 had enzymatic activity,
aminopeptidase-activated release of 7-AMC from alanine-AMC
was measured in 1F6, 1F6-pcDNA3 and clones highly over-
expressing 18kD or ALL bFGF isoform proteins (Figure 3). In line
with mRNA and protein expression, aminopeptidase activity was
increased up to five-fold in bFGF-overexpressing clones. Addition
of 350mM bestatin, a nonspecific aminopeptidase inhibitor, resul-
ted in a more than 90% inhibition of enzyme activity in all cell
lines (Po0.05). In contrast, the specific CD13-neutralising anti-
body WM15 (10mgml
 1) did not inhibit the enzymatic activity in
1F6 and 1F6-pcDNA3 cells, suggesting that CD13 is not involved in
the basal neutral aminopeptidase activity. In 1F6-18kD and 1F6-
ALL cells, however, exposure to WM15 resulted in a three-fold
reduction of total aminopeptidase activity, indicating that the
increased enzymatic activity in 1F6-18kD and 1F6-ALL cells is
mainly due to increased CD13 levels.
High CD13 expression in bFGF-overexpressing 1F6 clones
facilitates invasion, but not migration
CD13 has been implicated to be required for melanoma cell
invasion in ECM in vitro as well as in vivo (Menrad et al, 1993;
Fujii et al, 1995). Therefore, we determined whether the increased
CD13 expression observed in the highly bFGF-overexpressing
1F6 clones resulted in a higher invasive capacity. In contrast to 1F6
and 1F6-pcDNA3 cells, which did not show any invasion through
Matrigel 5mgfilter
 1 in the presence of 10% FCS used as a chemo-
attractant, highly increased invasion was observed for both
1F6-18kD and 1F6-ALL clones (Figure 4A). Figure 4B shows that
1F6-18kD and 1F6-ALL clones even invaded through Matrigel
20mgfilter
 1. Addition of 350mM bestatin resulted in complete
inhibition of the FCS-induced invasion (Po0.05). Exposure to
10mgml
 1 of the CD13-neutralising antibody WM15 also resulted
in a significant reduction of invasion (Po0.05). Toxicity of
bestatin and WM15 was determined by an MTT assay. Bestatin at
350mM resulted in a growth inhibition of approximately 10%, while
WM15 at 10mgml
 1 did not affect cell growth (data not shown).
The migratory capacity of 1F6 cells and bFGF-overexpressing
clones was determined by a wound assay. Figure 5A illustrates
that clones 1F6-18kD and 1F6-ALL clearly had a higher rate of
migration as compared to that of parent 1F6 and 1F6-pcDNA3 cells
(Po0.05). Exposure to 10mgml
 1 WM15 did not inhibit the
0
10
20
30
b
F
G
F
/
h
M
G
pcDNA3  L            HHL
18kD ALL
HMW
18kD
18kD ALL
pcDNA3 L      H        H       L
Nonspecific
40
A3            
A
B
Figure 1 Basic fibroblast growth factor mRNA and protein expression in
1F6 cells stably transfected with 18kD or ALL isoforms of bFGF. (A) Mean
ratios between bFGF and human b2-microglobulin (hMG) mRNAs in 1F6-
pcDNA3 and 1F6 clones with high (H) or low (L) 18kD or ALL bFGF
isoform proteins were determined by Light Cycler RT–PCR. The bFGF/
hMG ratio in 1F6-pcDNA3 cells was set at 1. (B) Basic fibroblast growth
factor proteins from the same cell lines were visualised by subjecting 20mg
protein per lane to Western blot.
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smigration rate (Figure 5B and C) indicating that CD13 activity is
not involved in this process.
Basic fibroblast growth factor-induced CD13 expression is
not due to increased mRNA stability
One possible mechanism for the increased CD13 expression obser-
ved in bFGF-overexpressing 1F6 cells is an increase in CD13
mRNA stability. To test this possibility, we determined the
degradation of CD13 mRNA in 1F6-pcDNA3 and bFGF-transfected
1F6 clones after incubation with the transcription inhibitor
actinomycin D for different time periods by Light-Cycler PCR.
From Figure 6 it can be seen that CD13 mRNA in 1F6-pcDNA3,
1F6-18kD and 1F6-ALL cells was degraded with similar half-lifes of
approximately 18h.
Basic fibroblast growth factor can induce expression of
CD13 transcripts from the myeloid promoter
CD13 transcriptional regulation can be mediated by the distal,
myeloid promoter, and a proximal, epithelial promoter (Shapiro
et al, 1991). We designed a primer set to specifically detect CD13
mRNA expression resulting from activity of the myeloid pro-
moter (CD13 MP). U937 and HL60 cells were included as posi-
tive controls for myeloid CD13 promoter activity. As a negative
control, Hep3B cells were used, since CD13 expression in this cell
line is the result of activity of the epithelial promoter only. While
no myeloid promoter fragment could be detected in Hep3B, 1F6
and 1F6-pcDNA3 cells (Figure 7, lanes 4–6), high levels of myeloid
promoter fragments were observed in 1F6 clones overexpressing
18kD and ALL bFGF isoforms (Figure 7, lanes 7–10). A second
primer set (CD13 MP/EP) was used to amplify fragments resulting
from activity of both the epithelial and the myeloid promoter. As
expected, positive bands were observed in all cell lines using this
primer set.
Increased CD13 expression is mediated by enhanced
activity of both the myeloid and epithelial promoter
Our RT–PCR analysis indicated that at least the CD13 myeloid
promoter is involved in the increased CD13 expression observed in
bFGF-overexpressing 1F6 clones. To further examine whether only
the myeloid or both the myeloid and epithelial CD13 promoters
were activated, transient transfections were performed using
reporter gene constructs encoding for either the myeloid promoter
(BstXI-luc) or the epithelial promoter (CD13-1.15-luc). To correct
for possible differences in transfection efficiency between parent
1F6 cells and bFGF-overexpressing clones, cotransfections were
performed with pRenilla-CMV. CD13 myeloid promoter activity
in clones 1F6-18kD-H and 1F6-ALL-H was, respectively, 4.5- and
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s2.8-fold induced. Interestingly, the activity of the epithelial
promoter was also induced up to 2.5-fold in both bFGF-over-
expressing clones (Figure 8). These data clearly indicate that,
although basal activity of the myeloid promoter in 1F6 cells was
about 2.5-fold higher as compared to the activity of the epithelial
promoter, both CD13 promoters are activated in bFGF-over-
expressing 1F6 cells.
CD13 expression correlates with bFGF expression in a
panel of human melanoma cell lines
Since we observed that bFGF overexpression can induce CD13
expression in human melanoma cells, we determined whether
there was a correlation between bFGF and CD13 mRNA expression
in a panel of melanoma cell lines. Indeed, the two cell lines, BRO
and BLM, with high bFGF expression also contained a high level
of CD13 mRNA, while low CD13 mRNA content was present in
Mel57, M14 and 1F6 cells expressing low levels of bFGF mRNA
(Figure 9A). A significantly positive correlation was calculated
between CD13 and bFGF mRNA expression (Po 0.05, R
2¼0.883).
In accordance with mRNA data, CD13 protein expression was only
observed in BRO and BLM cell lines containing high levels of bFGF
proteins (Figure 9B).
DISCUSSION
We report for the first time that overexpression of bFGF in human
melanoma cells mediates highly increased expression of CD13
mRNA and protein, which indicates that bFGF is involved in the
induction of an invasive cellular phenotype. The increased inva-
siveness of bFGF-overexpressing clones through Matrigel could be
attributed to high CD13 expression, since the specific monoclonal
antibody WM15 inhibited this process. In accordance with these
effects of bFGF overexpression, we found in a panel of human
melanoma cell lines a highly significant correlation between endo-
genous bFGF and CD13 mRNA expression as well as spontaneous
metastasis formation. These findings point towards an important
role for bFGF in the high metastatic potential of melanomas in
patients.
For our experiments, we made use of 1F6 cells with low endo-
genous bFGF levels that were transfected with vectors either
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Figure 4 Invasion of 1F6, 1F6-pcDNA3 and 1F6 clones highly
overexpressing 18kD or ALL bFGF isoform proteins in Matrigel. In the
upper compartment, 0.2 10
6 cells were added in 0.5% FCS-containing
medium. Spontaneous invasion was determined by medium containing
0.5% FCS in the lower compartment, while 10% FCS was used as a
chemoattractant in the lower compartment to induce invasion. The assay
was terminated at 48h. (A) Invasion of cells through Matrigel at
5mgfilter
 1 under 0.5 or 10% serum conditions. (B) Inhibition of 1F6-
18kD and 1F6-ALL invasion through Matrigel at 20mgfilter
 1 by addition of
350mM bestatin and 10mgml
 1 WM15. The 10% FCS-induced invasion of
clones 1F6-18kD and 1F6-ALL was set at 100%. Mean values (7s.d.) of
three independent experiments carried out in duplicate wells are shown.
*Indicates a significant difference (Po0.05) as compared to 10% FCS-
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Figure 5 Scratch wound assay for 1F6, 1F6-pcDNA3 and 1F6 clones
highly overexpressing 18kD or ALL bFGF isoform proteins. Migration of
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sencoding the 18kD isoform or ALL isoforms in an attempt to
distinguish between the variation in phenotypic behaviour induced
by the different proteins. The 18kD bFGF isoform functions as an
autocrine and paracrine growth factor and is mainly found in the
cytoplasm of cells and bound to heparan sulphate proteoglycans
(HSPGs) on the cell membrane. In contrast, the high molecular
weight (HMW) isoforms are located in the nucleus and are thought
to play a role in transcriptional regulation (Renko et al,
1990; Bugler et al, 1991; Florkiewicz et al, 1991; Quarto et al,
1991). Upon transfection, however, both 1F6-18kD and 1F6-ALL
clones expressed similar amounts of CD13, which suggests that
expression of the 18kD protein alone is sufficient for the induction
of CD13. Moreover, changes in morphology and growth rate were
similar between 1F6-18kD and 1F6-ALL clones.
Induction of CD13 expression by exogenous bFGF has
previously been described in human endothelial cells and is
required for vasculogenesis. In the study by Bhagwat et al (2001),
addition of the 18kD bFGF protein to serum-starved HUVECs
upregulated CD13 mRNA expression up to 2.5-fold. Although
bFGF was the most potent stimulator of CD13 expression in that
study, induction of CD13 protein was also observed when
endothelial cells were cultured under hypoxic conditions or were
treated with the angiogenic growth factors VEGF, TNFa or IGF-1.
Inhibition of CD13 expression by bestatin, amastatin or the
monoclonal-anti CD13 antibody MY7 resulted in a clear reduction
of capillary tube formation of HUVECs, while there was no effect
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sof these inhibitors on proliferation (Bhagwat et al, 2001). The
authors have also reported that exogenous bFGF could induce
CD13 expression in KS1767 Kaposi sarcoma cells (Bhagwat et al,
2001). Recently, Kehlen et al (2003) have shown induction of
CD13 expression upon stimulation of serum-starved 1736 thyroid
carcinoma cells with bFGF.
Repeatedly, we were not able to increase CD13 expression by
stimulating serum-starved 1F6 cells with exogenous recombinant
human bFGF, regardless efficient stimulation of cell proliferation
(data not shown). This finding indicates that the bFGF-mediated
induction of CD13 in 1F6 cells is an indirect effect of the
transformation process in itself, rather than a direct effect on CD13
promoter activity. Since CD13 can be detected on melanoma cells
(Elder et al, 1989; Menrad et al, 1993; Fujii et al, 1995), we are the
first to report that endogenous bFGF can mediate the expression
and activity of this protein.
Bestatin is a well-known chemical inhibitor of CD13 amino-
peptidase activity, which blocks the catalytic site of the enzyme in
a competitive manner. Although bestatin is often considered to
be specific for CD13, it also inhibits other aminopeptidases,
such as aminopeptidase B and leucine aminopeptidases (Scornik
and Botbol, 2001). High concentrations of bestatin (150–300mM)
clearly reduced invasion of HT1080 fibrosarcoma cells and
WM1158 melanoma cells through Matrigel (Menrad et al, 1993;
Fujii et al, 1996). WM15 is a monoclonal antibody that specifi-
cally neutralises CD13 activity. WM15 has been shown to inhibit
invasion through Matrigel, as described for SN12M renal-cell
carcinoma, HT1080 fibrosarcoma and A375 melanoma cells (Saiki
et al, 1993). In our bFGF-overexpressing 1F6 clones, both bestatin
and WM15 almost completely abrogated the enhanced invasive
capacity. This observation indicates that the increased CD13
expression and activity in the bFGF-overexpressing clones is
mainly responsible for the facilitated invasive potential.
The activity of the myeloid and the epithelial promoters of CD13
is believed to be mutually exclusive (Shapiro et al, 1991). As a
result, expression of CD13 protein in a particular cell type is
thought to be mediated by activation of either the myeloid or the
epithelial promoter. We now show that both CD13 promoters can
be activated in response to bFGF overexpression. Although in 1F6
cells the basal expression of the myeloid promoter was consistently
found to be higher than the activity of the epithelial promoter,
both activities were increased to the same extent, up to four-fold in
clones 1F6-18kD and 1F6-ALL. We do not know if the current
results are specific for melanoma cells, or whether the use of the
more sensitive techniques would also allow to detect upregulation
of both promoters in other cell types. While initial CD13 promoter
studies were performed with chloramphenicol acetyl transferase
(CAT) assays and Northern blots (Shapiro et al, 1991), we made
use of RT–PCR and promoter-luciferase assays allowing us to
detect the activities of both promoters in 1F6 melanoma cells and
clones.
Recently, induction of CD13 expression by bFGF in endothelial
cells was shown to be regulated by two Ras-mediated signalling
pathways that have been implicated in the transition of quiescent
to active endothelium: the mitogen-activated protein kinase
(MAPK) and phosphoinositide-3 kinase/AKT (PI-3K/AKT) path-
ways (Bhagwat et al, 2003). Petrovic et al (2003) have demon-
strated in activated endothelial cells that CD13 transcription was
induced by RAS/MAPK-mediated phosphorylation of the trans-
cription factor Ets-2 resulting in increased activity of the epithelial
CD13 promoter. In our bFGF-overexpressing 1F6 clones, phospho-
AKT and phospho-p38 MAPK levels were increased as compared
to basal levels in parent 1F6 cells, while basal phospho-ERK1/2
MAPK was not further increased (Fontijn et al, unpublished data).
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Figure 8 CD13 myeloid and epithelial promoter activity in 1F6, 1F6-
pcDNA3 and 1F6 clones highly overexpressing 18kD or ALL bFGF isoform
proteins. Luciferase-coupled CD13 myeloid (MP) or epithelial (EP)
promoter construct (1mg) and pGL2-basic vector were transiently
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5ng pRL-CMV was performed to correct for differences in transfection
efficiency between cell lines. Mean values of relative light units
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Figure 9 (A) Correlation between bFGF and CD13 mRNA expression
in a panel of human melanoma cell lines. cDNAs were analysed for bFGF
and CD13 mRNA expression with Light Cycler RT–PCR and plotted as
mean relative expression ratios between bFGF, CD13 and human b2-
microglobulin (hMG) of two independent experiments. Significance was
determined with the Spearman’s correlation test. (B) Basic fibroblast
growth factor and CD13 protein expression in a panel of human melanoma
cell lines. Of each cell line, 20mg (bFGF) or 50mg (CD13) protein of total
cell lysates was subjected to Western blot. Blots were stripped and stained
with anti-b-actin antibody to confirm equal protein loading.
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sWe are further investigating the possible contribution of the PI-
3K/AKT and p38 MAPK signalling pathways in the increased CD13
expression in bFGF-overexpressing 1F6 clones.
In general, high CD13 expression in solid tumours in patients
is considered as an unfavourable factor. Few clinical studies are
available, among which are observations in pancreatic carcinoma,
colon carcinoma and thyroid carcinoma, which will be described
shortly. CD13 protein expression was detected in 48% of pan-
creatic carcinoma patients and was significantly associated with a
shorter median survival (Ikeda et al, 2003). The disease-free and
overall survival rate for patients with CD13-positive colon
carcinoma was significantly lower than that for patients without
CD13 expression (Hashida et al, 2002). Kehlen et al (2003) have
shown that CD13 expression in undifferentiated thyroid carcino-
mas was higher than that in papillary or follicular thyroid carcino-
mas, suggesting that it is a marker for differentiation. Clinical
studies on CD13 expression in cutaneous melanoma are yet to be
carried out.
It can be hypothesized that the presence of CD13 in melanoma
patients will also be associated with poor prognosis. As a rationale,
it has been shown in vitro that inhibition of CD13 aminopeptidase
activity can reduce the invasive capacity of WM1158 and A375M
melanoma cells through Matrigel (Menrad et al, 1993; Saiki et al,
1993). Upon transfection of CD13 into A375M and A2058
melanoma cells, increased degradation of type IV collagen and
invasion in ECM have been observed (Fujii et al, 1995). These
CD13-transfected cells showed a significantly augmented lung-
colonising potential in nude mice (Fujii et al, 1995). The obser-
vations are in agreement with our data that 1F6 cells could hardly
invade through Matrigel, but their invasive capacity is greatly
facilitated in the case of CD13 overexpression. As proof of concept,
in our panel of human melanoma cell lines, we found a clear
correlation between bFGF and CD13 mRNA and protein expres-
sion (Figure 9). High bFGF and CD13 protein expression could be
detected in melanoma cell lines BRO and BLM, being aggressive
cell lines on the basis of a high in vitro and in vivo growth rate.
Furthermore, BLM and BRO cells grown as subcutaneous xeno-
grafts in nude mice have a very high rate of spontaneous meta-
stasis formation (Lockshin et al, 1985; Van Muijen et al, 1991).
Bestatin has been studied for its therapeutic usefulness in the
clinic in the past, since the compound was considered to have
immunopotentiating activity (Ota, 1991). In a prospective
randomised trial in adult nonlymphocytic leukaemia, prolongation
of remission duration and survival was achieved with bestatin
added to maintenance chemotherapy in elderly patients (Ota et al,
1986). Prospective randomised clinical trials in various solid
tumours contained either too few patients or were negative to
demonstrate a beneficial effect on survival (Ota, 1991). In a recent,
randomised double-blind placebo-controlled trial by Ichinose et al
(2003), bestatin was given for its aminopeptidase inhibiting,
immunostimulant and antitumour activity to patients with
completely resected stage I squamous-cell lung carcinoma. Of the
402 patients that entered the study, it appeared that the overall
survival and cancer-free survival were both significantly different
in favour of the bestatin-treated group. Since we found a clear
correlation between bFGF and CD13 expression and invasiveness
of melanoma cells, the incorporation of bestatin in a clinical trial
in stage II melanoma patients should be considered with the aim of
preventing the development of metastases and to improve survival.
In conclusion, our data indicate that high bFGF expression in
human melanoma cells is a major mechanism of the upregulation
of CD13 resulting in enhanced invasive capacity and metastatic
behaviour. Selective inhibition of CD13, or even of bFGF itself,
should therefore be an attractive strategy for the treatment of
advanced melanoma, but likely also for adjuvant treatment in stage
II disease.
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